The origins of new drugs [1]

Nature Biotechnology

Volumn 23, Issue 5, 2005, Pages 529-530

  Kneller, Robert ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

RIBOSOME DNA; ROFECOXIB; DRUG;

DRUG INDUSTRY; DRUG MARKETING; FOOD AND DRUG ADMINISTRATION; LETTER; PATENT; PRIORITY JOURNAL; BIOTECHNOLOGY; DRUG APPROVAL; DRUG DESIGN; ORGANIZATION AND MANAGEMENT; STATISTICS; UNITED STATES; UNIVERSITY;

BIOTECHNOLOGY; DRUG APPROVAL; DRUG DESIGN; DRUG INDUSTRY; PHARMACEUTICAL PREPARATIONS; PUBLIC SECTOR; UNITED STATES; UNIVERSITIES;

EID: 22844433803     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt0505-529     Document Type: Letter

References (6)

1. Cockburn, I. & Henderson, R. Public-Private Interaction and the Productivity of Pharmaceutical Research. National Bureau of Economic Research (NBER) Working Paper 6018 (NBER, Cambridge, MA, 1997).
2. Powell, W.W., Korput, K.W. & Smith-Doerr, L. Administr. Sci. Quart. 41, 116-145 (1996).
3. Murray, F. Res. Policy 31, 1389-1403 (2002).
4. Henderson, R., Orsenigo, L. & Pisano, G.P. in Sources of Industrial Leadership, Studies of Seven Industries (eds. Mowery, D. & Nelson, R.) 267-311 (Cambridge University Press, Cambridge, UK, 1999).
5. McKelvey, M. Evolutionary Innovations, the Business of Biotechnology (Oxford University Press, Oxford, 1996).
6. Zucker, L.G. & Darby, M.R. Proc. Natl. Acad. Sci. USA 93, 12709-12716 (1996).